Reported results
- Total revenues were $19.0 million for the third quarter of 2026.
- Emrosi revenues were $9.0 million for the third quarter of 2026.
- The Company’s gross margin was 69% for the third quarter of 2026.
- GAAP Net Loss was $1.3 million for the third quarter of 2026.
- Non-GAAP Adjusted EBITDA was $3.516 million for the third quarter of 2026.
- Emrosi total prescriptions (TRx) were approximately 40,000 for the third quarter of 2026.
Notes
Beginning in the first quarter of 2026, the Company no longer excludes short-term research and development expenses from Non-GAAP Adjusted EBITDA results; prior period Non-GAAP Adjusted EBITDA results have been revised to reflect this change.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
